Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45


Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase.

Winters M, DuHadaway JB, Pham KN, Lewis-Ballester A, Badir S, Wai J, Sheikh E, Yeh SR, Prendergast GC, Muller AJ, Malachowski WP.

Eur J Med Chem. 2018 Nov 14;162:455-464. doi: 10.1016/j.ejmech.2018.11.010. [Epub ahead of print]


Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.

Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR.

Clin Cancer Res. 2018 Sep 28. doi: 10.1158/1078-0432.CCR-18-0814. [Epub ahead of print]


CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.

Cancer Res. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.


Discovery of IDO1 Inhibitors: From Bench to Bedside.

Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ.

Cancer Res. 2017 Dec 15;77(24):6795-6811. doi: 10.1158/0008-5472.CAN-17-2285. Review.


RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus.

Mandik-Nayak L, DuHadaway JB, Mulgrew J, Pigott E, Manley K, Sedano S, Prendergast GC, Laury-Kleintop LD.

Dis Model Mech. 2017 Nov 1;10(11):1313-1322. doi: 10.1242/dmm.029835. Epub 2017 Sep 7.


Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Merlo LMF, Grabler S, DuHadaway JB, Pigott E, Manley K, Prendergast GC, Laury-Kleintop LD, Mandik-Nayak L.

Clin Immunol. 2017 Jun;179:8-16. doi: 10.1016/j.clim.2017.01.016. Epub 2017 Feb 20.


IDO1 is an Integral Mediator of Inflammatory Neovascularization.

Mondal A, Smith C, DuHadaway JB, Sutanto-Ward E, Prendergast GC, Bravo-Nuevo A, Muller AJ.

EBioMedicine. 2016 Dec;14:74-82. doi: 10.1016/j.ebiom.2016.11.013. Epub 2016 Nov 9.


IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism.

Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L.

J Immunol. 2016 Jun 1;196(11):4487-97. doi: 10.4049/jimmunol.1600141. Epub 2016 Apr 25.


Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.

Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA.

Oncotarget. 2016 Apr 19;7(16):21812-24. doi: 10.18632/oncotarget.7840.


O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Malachowski WP, Winters M, DuHadaway JB, Lewis-Ballester A, Badir S, Wai J, Rahman M, Sheikh E, LaLonde JM, Yeh SR, Prendergast GC, Muller AJ.

Eur J Med Chem. 2016 Jan 27;108:564-576. doi: 10.1016/j.ejmech.2015.12.028. Epub 2015 Dec 17.


Aryl hydrocarbon receptor control of a disease tolerance defence pathway.

Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, Bianchi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Zelante T, Funakoshi H, Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P.

Nature. 2014 Jul 10;511(7508):184-90. doi: 10.1038/nature13323.


1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis.

Pigott E, DuHadaway JB, Muller AJ, Gilmour S, Prendergast GC, Mandik-Nayak L.

Autoimmunity. 2014 Sep;47(6):409-18. doi: 10.3109/08916934.2014.914507. Epub 2014 May 6.


IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.

Merlo LMF, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, Mandik-Nayak L.

J Immunol. 2014 Mar 1;192(5):2082-2090. doi: 10.4049/jimmunol.1303012. Epub 2014 Jan 31.


IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC.

Int Immunol. 2014 Jul;26(7):357-67. doi: 10.1093/intimm/dxt073. Epub 2014 Jan 8.



Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC.

J Radiat Oncol. 2013 Sep 1;2(3). doi: 10.1007/s13566-013-0111-x.


The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis.

Simionescu-Bankston A, Leoni G, Wang Y, Pham PP, Ramalingam A, DuHadaway JB, Faundez V, Nusrat A, Prendergast GC, Pavlath GK.

Dev Biol. 2013 Oct 1;382(1):160-71. doi: 10.1016/j.ydbio.2013.07.004. Epub 2013 Jul 16.


IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC.

Oncoimmunology. 2012 Dec 1;1(9):1460-1468.


Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models.

Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C, Declercq W, Callewaert N, Prendergast GC, Degterev A, Yuan J, Vandenabeele P.

Cell Death Dis. 2012 Nov 29;3:e437. doi: 10.1038/cddis.2012.176.


RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.

Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, Kocher ON, Brown LF, Toker A, Prendergast GC, Benjamin LE.

Cancer Res. 2013 Jan 1;73(1):50-61. doi: 10.1158/0008-5472.CAN-11-3055. Epub 2012 Nov 7.


IDO is a nodal pathogenic driver of lung cancer and metastasis development.

Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ.

Cancer Discov. 2012 Aug;2(8):722-35. doi: 10.1158/2159-8290.CD-12-0014. Epub 2012 Jul 19.


Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase.

Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, Muller AJ, Laury-Kleintop LD, Prendergast GC.

Cancer Biol Ther. 2011 Dec 15;12(12):1050-8. doi: 10.4161/cbt.12.12.18142. Epub 2011 Dec 15.


Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection.

Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper AM, Yap GS, Arditi M, Shimada K, Duhadaway JB, Prendergast GC, Basaraba RJ, Mellor AL, Munn DH, Aliberti J, Karp CL.

J Infect Dis. 2012 Jan 1;205(1):152-61. doi: 10.1093/infdis/jir621. Epub 2011 Oct 11.


RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac.

Huang M, Satchell L, Duhadaway JB, Prendergast GC, Laury-Kleintop LD.

J Cell Biochem. 2011 Jun;112(6):1572-84. doi: 10.1002/jcb.23069.


Genomic profiling of miRNAs in two human lens cell lines.

Tian L, Huang K, DuHadaway JB, Prendergast GC, Stambolian D.

Curr Eye Res. 2010 Sep;35(9):812-8. doi: 10.3109/02713683.2010.489182.


Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC.

Cancer Immunol Immunother. 2010 Nov;59(11):1655-63. doi: 10.1007/s00262-010-0891-4. Epub 2010 Jul 17.


Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.

Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, Prendergast GC.

Mol Cancer Ther. 2010 Jun;9(6):1864-71. doi: 10.1158/1535-7163.MCT-10-0185. Epub 2010 Jun 8.


Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.

Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC.

Cancer Res. 2010 Mar 1;70(5):1845-53. doi: 10.1158/0008-5472.CAN-09-3613. Epub 2010 Feb 16. Erratum in: Cancer Res. 2010 Apr 15;70(8):3414.


Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17073-8. doi: 10.1073/pnas.0806173105. Epub 2008 Oct 24.


Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, Prendergast GC, Muller AJ.

J Med Chem. 2008 Aug 28;51(16):4968-77. doi: 10.1021/jm800512z. Epub 2008 Jul 30.


Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging.

Ramalingam A, Duhadaway JB, Sutanto-Ward E, Wang Y, Dinchuk J, Huang M, Donover PS, Boulden J, McNally LM, Soler AP, Muller AJ, Duncan MK, Prendergast GC.

Cancer Res. 2008 Mar 15;68(6):1683-90. doi: 10.1158/0008-5472.CAN-07-6072.


Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ.

J Med Chem. 2008 Mar 27;51(6):1706-18. doi: 10.1021/jm7014155. Epub 2008 Mar 5. Erratum in: J Med Chem. 2008 Nov 27;51(22):7325.


A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.

Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ.

Oncogene. 2008 May 1;27(20):2851-7. Epub 2007 Nov 19.


RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells.

Huang M, Duhadaway JB, Prendergast GC, Laury-Kleintop LD.

Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2597-605. Epub 2007 Oct 19.


mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition.

Kamasani U, Duhadaway JB, Alberts AS, Prendergast GC.

Cancer Biol Ther. 2007 Sep;6(9):1422-7. Epub 2007 Jun 5.


Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.


Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression.

Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, Prendergast GC.

Cancer Res. 2007 Jan 1;67(1):100-7.


The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition.

Casal E, Federici L, Zhang W, Fernandez-Recio J, Priego EM, Miguel RN, DuHadaway JB, Prendergast GC, Luisi BF, Laue ED.

Biochemistry. 2006 Oct 31;45(43):12917-28.


Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II.

Masumi A, Aizaki H, Suzuki T, DuHadaway JB, Prendergast GC, Komuro K, Fukazawa H.

Biochem Biophys Res Commun. 2005 Oct 21;336(2):572-8.


Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC.

Nat Med. 2005 Mar;11(3):312-9. Epub 2005 Feb 13.


Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts.

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC.

Cancer Biol Ther. 2004 Dec;3(12):1236-42. Epub 2004 Dec 14.


Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition.

Kamasani U, Huang M, Duhadaway JB, Prochownik EV, Donover PS, Prendergast GC.

Cancer Res. 2004 Nov 15;64(22):8389-96.


Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.

DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.

Oncogene. 2003 Jun 5;22(23):3578-88.


Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation.

Muller AJ, Baker JF, DuHadaway JB, Ge K, Farmer G, Donover PS, Meade R, Reid C, Grzanna R, Roach AH, Shah N, Soler AP, Prendergast GC.

Mol Cell Biol. 2003 Jun;23(12):4295-306.


Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer.

DuHadaway JB, Lynch FJ, Brisbay S, Bueso-Ramos C, Troncoso P, McDonnell T, Prendergast GC.

J Cell Biochem. 2003 Feb 15;88(3):635-42.


Bin1 mediates apoptosis by c-Myc in transformed primary cells.

DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC.

Cancer Res. 2001 Apr 1;61(7):3151-6.

Supplemental Content

Loading ...
Support Center